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Received December 31, 2013; accepted January 14, 2014AbstractAcute esophageal variceal hemorrhage is a terrible complication of portal hypertension and. rebleeding is very common in survivors of acute
variceal bleeding. Traditional medical management options include the use of vasoconstrictor, balloon tamponade, and endoscopic therapy.
Though endoscopic therapy has achieved successful hemostasis in the majority of acute variceal bleeding episodes, the outcome is usually
dismal when such therapy fails. Transjugular intrahepatic portosystemic stent shunt (TIPS) was invented to decompress portal hypertension, but
is now widely used in Western countries to treat patients with refractory variceal hemorrhage or refractory ascites. By contrast, TIPS has not
been commonly used in Asia. In this article, I have reviewed the role of TIPS in the management of portal hypertensive bleeding, which will
hopefully be useful for clinicians facing variceal bleeding that is not amenable to endoscopic therapies.
Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Acute esophageal variceal hemorrhage (AEVH) is a
devastating complication of portal hypertension. The natural
history of AEVH shows that its associated mortality may be as
high as 40%, with a high incidence of early rebleeding, i.e., in
about 30e50% of survivors.1,2 Fortunately, because of the
advancement of medical and endoscopic therapies, the mor-
tality rate has been reduced to approximately 15% in recent
years. The factors responsible for AEVH are not well delin-
eated. Portal pressure, variceal pressure, and the tension of the
esophageal variceal wall are factors that have been demon-
strated to be associated with AEVH. Hepatic venous pressureConflicts of interest: The author declares that there are no conflicts of interest
related to the subject matter or materials discussed in this article.
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patients with variceal rupture.3 Poor hepatic reserve and an
abundance of red color signs on the large varices are also
important factors predictive of AEVH.4
A few treatment options are available for the management
of AEVH. Vasoconstrictors and endoscopic therapy are
most frequently used to control AEVH. Up to 20e30% of
these procedures may fail.1,5e8 Among various factors,
HVPG > 20 mmHG measured early after admission has been
documented to be an important prognostic factor predictive of
treatment failure.9 To relieve portal pressure, beta blockers
such as propranolol, nadolol, or carvedilol have been adopted
to prevent variceal rebleeding.1,10e12 However, during acute
bleeding, these drugs are not useful in hemostasis and are
contraindicated in patients with unstable vital signs. By
contrast, TIPS is used to alleviate portal hypertension, and
could lead to cessation of torrential variceal bleeding as well
as prevention of further rebleeding. We undertake a review of
the development and application of TIPS on the therapy ofociation. All rights reserved.
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widely used to rescue patients with intractable variceal
bleeding.
2. Development of TIPS
In 1969, Rosch and coworkers13 first introduced the
concept of TIPS through the use of animal studies. In 1982,
Colapinto et al14 were the first to apply TIPS to six patients
with advanced cirrhosis and portal hypertension and life-
threatening esophageal variceal bleeding. The varices were
obliterated angiographically, and an intrahepatic portosyste-
mic shunt was created by inflating the 9e12 mm diameter
angioplasty balloon of a Gruntzig dilatation catheter in the
needle tract between the portal and hepatic veins. Conse-
quently, the portal venous pressure was reduced by 20%.
Although three patients survived the initial hemorrhage, all six
patients died within 6 months despite the patency of the shunts
that were examined at postmortem.14 Subsequently, Palmaz
et al15 substantially advanced the field when they designed an
expandable shunt, which became the basis of the current
standard TIPS procedure to maintain long-term patency. TIPS
was introduced into clinical practice in 1988.16 However, Ring
and associates17 modified the technique by eliminating the
transhepatic catheter and implanting a flexible Wallstent,
which transformed TIPS into a 1e2-hour procedure with a
high success rate and a low complication rate.18 Currently,
TIPS is usually initiated through puncture of the right internal
jugular vein, via the superior vena cava, into the right hepatic
vein. Transhepatic portography was initially applied to
recognize the portal vein for puncture at an early stage of
development for TIPS. This approach has gradually been
replaced by ultrasound-guided localization. Under fluoro-
scopic control, the major branch of the right portal vein could
be punctured, avoiding the risk of bleeding evoked by percu-
taneous puncture of the portal vein. Thereafter, the Wallstent is
usually dilated to 8e10 mm. If the varices are still filling
rapidly, they may then be catheterized and embolized. It has
been observed that 10% of patients may require overdilatation
of a stent using a 12-mm balloon.19
After insertion of a stent, stenosis and occlusion may
develop gradually, which in turn lead to reversal of portal
hypertension. A dysfunction rate up to 80% was noted in the
bare stents. Stents covered with polytetrafluoroethylene
(PTFE) was demonstrated to improve shunt patency by
avoiding the pseudointimal hyperplasia. Primary patency
could be improved from 36% with bare stents to 76% with
covered stents, with a significant reduction of hepatic en-
cephalopathy and similar survival rates.20
The first indication for TIPS was acute variceal hemorrhage
that was not amenable to endoscopic and pharmacological
therapy. Subsequently, TIPS was also used in the prevention of
gastroesophageal variceal rebleeding, ectopic variceal
bleeding, portal hypertensive gastropathy bleeding, and re-
fractory ascites. To date, there have been a multitude of studies
published related to TIPS.21,22 Most of these studies used bare
stents, unless a variation was mentioned specifically. Thisreview focuses on the application of TIPS in the treatment of
portal hypertensive bleeding.
3. TIPS for refractory esophageal variceal bleeding
The first indication for TIPS is refractory variceal bleeding,
which is generally regarded as those variceal episodes that are
not readily controlled by combination of vasoconstrictors and
endoscopic therapy. In 1992, LaBerge et al23 performed TIPS
in 24 patients in whom endoscopic injection sclerotherapy
(EIS) failed to control variceal bleeding. Hemostasis was
achieved in the 12 patients with active bleeding, and the
mortality rate at 1 month was 20%. In another series consisting
of 59 patients, including 23 patients with active bleeding,
bleeding control failed in two patients. The rebleeding rate
was up to 31% and the mortality rate was 35% during the
index hospitalization. Overall, serious complications were
encountered in eight patients (14%).24
In 1996, Sanyal et al25 enrolled 30 patients with actively
bleeding esophageal varices or contiguous gastric varices
despite sclerotherapy for rescue TIPS insertion. TIPS was
successfully placed in 29 patients and hemostasis was ach-
ieved in all 29 patients. The 6-week survival rate was 60%.25
Banares and associates26 used salvage TIPS for variceal
bleeding uncontrolled by medical and endoscopic therapy in
56 decompensated cirrhosis patients. Hemostasis was achieved
in 95% of these cases. Eight patients (15%) had recurrent
bleeding at 1 month after TIPS, and seven died during the 1st
week after the procedure. The mortality rate at 30 days was
28%.26 A similar study from Azoulay et al,27 who performed
salvage TIPS within 3 hours after endoscopy, showed that
hemostasis was achieved in 90% of cases and 10% had
persistent bleeding. Early rebleeding was 7% and mortality at
30 days was 29%. The actuarial survival following salvage
TIPS was 51.7% at 1 year.27 Other similar studies showed that
TIPS can be helpful for patients with acute variceal bleeding
in whom medical and endoscopic therapy has failed.28e30
However, an appreciably high 1 month mortality rate up to
35% may be encountered.
4. Early use of TIPS in acute variceal bleeding with a high
risk of treatment failure
HVPG > 20 mmHg has been noted to be an important
factor predicting treatment failure in patients with acute var-
iceal bleeding. Monescillo et al31 randomized 116 cirrhotic
patients with acute variceal bleeding who had
HVPG  20 mmHg to receive TIPS within 24 hours of
admission or be categorized in the non-TIPS group. The re-
sults showed that early TIPS had a reduced treatment failure as
compared to the non-TIPS group (12% vs. 50%). The in-
hospital and 1-year mortality rates were also significantly
reduced in the early-TIPS group (11% and 31%, respec-
tively).31 However, a single session of sclerotherapy was
applied in patients randomized to the non-TIPS group, which
has been shown to be inferior to banding ligation in the control
of active variceal hemorrhage.5 Moreover, aside from in
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most hospitals.
However, patients with Child-Pugh Class B or C with
persistent bleeding revealed through endoscopy were regarded
as high risk for treatment failure. Garcia-Pagan et al32 per-
formed a controlled study to compare TIPS and pharmaco-
therapy combined with endoscopic variceal ligation (EVL) in
these 63 high risk acute variceal bleeding patients. Among the
early TIPS group, a PTFE-covered stent was inserted within
72 hours of admission.32 After a median follow-up of 16
months, rebleeding or failure to control bleeding occurred in
45% of patients in the pharmacotherapy-EVL group as
compared with 3% in the early TIPS group (p ¼ 0.0001). The
1-year actuarial survival was 61% in the pharmacotherapy-
EVL group versus 86% in the early-TIPS group (p < 0.001).
Additionally, serious adverse events were similar between the
two treatment groups. Surprisingly, the incidence of hepatic
encephalopathy was higher in the pharmacotherapy-EVL
group than the early TIPS group (29% vs. 15%). Thus, early
TIPS was suggested for patients with cirrhosis who had acute
variceal bleeding and high risk for treatment failure.
Is early TIPS really more effective than pharmacotherapy-
EVL in the control of acute variceal hemorrhage? The out-
comes of patients in the control arm of this study were noted to
be worse than previous studies33; thus, overestimation of the
actual benefits of TIPS over standard therapy has been ques-
tioned.34 Furthermore, 296 patients with varied reasons or who
met the exclusion criteria had been excluded from that
controlled trial. This may imply that a small proportion of
patients with acute esophageal variceal bleeding may actually
require early use of TIPS. As shown in the study by Augustin
et al,34 the combination of vasoconstrictor, antibiotics, and
EVL after acute esophageal variceal bleeding is associated
with very low mortality. Only Child-Pugh Class C patients
with baseline creatinine level higher than 1.0 mg/dL carried a
high mortality rate up to 46% as compared with 8% if creat-
inine level was less than 1.0 mg/dL. Our previous study
revealed that patients with active variceal bleeding treated
with emergency EVL could achieve a 97% successful hemo-
stasis and 30-day mortality was 19%.5 Based on these studies,
the selection of patients suitable for early TIPS appears to
require further investigation. If the incidence of hepatic en-
cephalopathy was indeed reduced in patients receiving early
TIPS compared with those in the pharmacotherapy-EVL
group, early TIPS should be considered in those patients
with a high risk of treatment failure.
5. TIPS versus surgical shunt for acute esophageal
variceal bleeding
Surgical shunt, devascularization, and esophageal trans-
action had been widely adopted in the past to control variceal
bleeding. Currently, surgical measures to decompress portal
hypertensive bleeding have been largely discarded by most
cardiovascular surgeons except those who strongly advocate
the approach.35,36 Orloff et al37 performed a controlled study
to compare emergency portacaval shunt (EPCS) and TIPS inpatients with cirrhosis “all comers” with acute esophageal
variceal bleeding. A total of 154 patients were enrolled, and
EPCS or TIPS was initiated within 24 hours of variceal
bleeding. The patients' follow-up duration was primarily in the
5e10 year range. TIPS was successful in controlling variceal
bleeding for 30 days in 80% of patients, but long-term control
of variceal bleeding was achieved in only 22%. By contrast,
EPCS controlled variceal bleeding immediately and perma-
nently in 97% of patients (p < 0.001). Encephalopathy
occurred with a threefold greater frequency following TIPS
than after EPCS (61% vs. 21). The survival rate was signifi-
cantly greater following EPCS than after TIPS (p < 0.001).
This study suggested that in unselected patients with cirrhosis
and acute esophageal variceal bleeding, EPCS could be a first-
line emergency therapy. However, it is difficult to achieve such
favorable outcomes by use of EPCS in other institutions.
Contrary to the report of early TIPS by Garcia-Pagan et al,32
the outcomes of early-TIPS by Orloff37 were apparently not
as favorable and it is difficult to explain the discrepancy.
6. Controlled studies of TIPS versus endoscopic therapy
for prevention of esophageal variceal rebleeding
Prior to the introduction of TIPS, beta blockers and endo-
scopic therapy have been widely used to prevent esophageal
variceal rebleeding.10,38e40 Many studies have been under-
taken to compare the relative effectiveness and safety between
TIPS and endoscopic therapy or beta blockers. The recurrent
bleeding rates associated with TIPS ranged from 10% to 24%,
whereas it was approximately 26e57% among patients
receiving endoscopic therapy. Hepatic encephalopathy was
generally more common in patients treated with TIPS.
Moreover, TIPS is associated with high rates of shunt stenosis
and occlusion,41e45 potentially because of the use of bare
stents. A meta-analysis including 11 trials with 811 patients
revealed that variceal rebleeding was significantly more
frequent with endoscopic therapy (47%) compared with TIPS
(19%). However, the use of TIPS did not improve survival.46
Thus, TIPS is not considered to be the first-line choice in
the prevention of esophageal variceal rebleeding.
Among the trials included in the analysis,45 most studies
adopted EIS as endoscopic therapy. Only three studies used
EVL.46e48 Moreover, the rebleeding rates associated with
EVL in these studies ranged from 42% to 59%, percentages
that were remarkably higher than those in other studies
demonstrating the superiority of EVL over sclerotherapy.49,50
EVL plus beta blocker is now regarded as the therapy of
choice to prevent esophageal variceal bleeding.1,51 Interest-
ingly, only two studies have compared EVL plus propranolol
versus TIPS in the prevention of variceal rebleeding.42,52 The
rebleeding rate was 30% in the combination group, compared
with 19% in the TIPS group, without a statistically significant
difference. Hepatic encephalopathy was found significantly
more often in the TIPS group (40%) than in the combination
group (20%). Based on these studies, it can be concluded that
TIPS cannot be recommended as the first-choice treatment for
prevention of variceal rebleeding.
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variceal rebleeding
Drug therapy using a combination of beta blocker and
isosorbide-5-mononitrate has been shown to be superior to or
comparable to EVL in the prevention of esophageal variceal
rebleeding.53e55 Until now, only one study had compared
TIPS and drug therapy for prevention of esophageal variceal
rebleeding.56 The study enrolled 91 patients and showed that
rebleeding occurred in 13% of TIPS-treated patients versus
39% of drug-treated patients. Encephalopathy was more
frequent in TIPS than in drug-treated patients and the identi-
fied cost of therapy was double for TIPS-treated patients.
However, the 2-year survival probability between the two
treatments was identical. Thus, TIPS is suggested not to be
used as a first-line treatment.
8. TIPS versus surgical shunt for prevention of
esophageal variceal rebleeding
TIPS was created as a substitute for a surgical shunt in the
treatment of portal hypertension. Consequently, it is probable
that fewer shunt operations have occurred worldwide now that
TIPS has become more widely available. However, controlled
studies comparing between TIPS and shunt operation are also
rarely reported. A controlled trial in 2006 comparing distal
splenorenal shunt (DSRS) and TIPS in patients in whom
medical therapy failed showed that the rebleeding rate was
5.5% in the DSRS group and 10.5% in the TIPS group, not a
significant difference.57 Also, the incidence of hepatic en-
cephalopathy and survival were similar between both thera-
pies. It appears that patients with esophageal variceal bleeding
in whom medical therapy failed and with good liver reserve
can be treated with either TIPS or shunt surgery.
9. TIPS for gastric variceal hemorrhage
It is well recognized that the general incidence of gastric
variceal bleeding is significantly lower than that of esophageal
variceal bleeding. However, rupture of gastric varices usually
results in more severe hemorrhage and a higher mortality rate
than esophageal varices.1,2 The optimal method to halt
bleeding gastric varices is still an unresolved issue. A variety
of methods including EIS, thrombin injection, EVL, use of
detachable snares, endoscopic obturation using tissue adhe-
sives (glue), TIPS, balloon-occluded retrograde transvenous
obliteration (BRTO), and surgery have been used for the
management of bleeding gastric varices with some suc-
cess.58,59 Endoscopic obturation with cyanoacrylate (histo-
acryl or glue) has increasingly garnered support among
medical practitioners worldwide, except for in the United
States.59
Many studies have demonstrated that TIPS is feasible for
patients with gastric variceal hemorrhage. Two studies from
England and France used TIPS to prevent rupture of gastric
varices in patients with refractory bleeding.60,61 Hemostasis
was achieved in 90e96% of patients. The follow-up periodwas 7 months and 1 year, respectively. Rebleeding rates were
similar between the two studies, i.e., 29% and 31%, respec-
tively. These results suggested that TIPS could be used in
patients with cirrhosis and refractory gastric variceal bleeding
and were effective in achieving hemostasis as well as pre-
venting rebleeding. The other studies also revealed that the use
of TIPS in the management of gastric varices was as effective
as its use in bleeding esophageal varices.62,63
10. TIPS versus glue injection for gastric variceal
hemorrhage
A retrospective analysis from the United Kingdom showed
that the rebleeding rates within 30 days were significantly
lower in TIPS patients than in patients using glue (15% vs.
30%, p ¼ 0.005).64 However, during the 6-month follow-up,
rebleeding rates were 20% and 35%, respectively. TIPS as a
therapy was significantly more expensive than glue therapy,
though survival rates did not differ between the two groups.
The other retrospective study from the United States showed
that glue injection was similar to TIPS in controlling gastric
variceal bleeding as well as preventing variceal rebleeding and
survival.65 However, the TIPS group had a higher rate of long-
term morbidity requiring hospitalization (41% with a TIPS vs.
1.6% in the glue group, p < 0.0001).
We performed a prospective, randomized controlled trial
comparing TIPS and glue therapy.66 Our study enrolled 72
patients with acute gastric variceal hemorrhage that was
initially controlled with vasoconstrictor and enodscopic ther-
apy. After a median follow-up of 33 months, gastric variceal
rebleeding was significantly lower in the TIPS group than in
the glue group (11% vs. 38%, p ¼ 0.01). Survival and com-
plications were similar in both groups. Based on our trial, we
suggested that TIPS could be the first choice in patients pre-
senting with acute gastric variceal hemorrhage.
11. TIPS versus BRTO for gastric variceal hemorrhage
BRTO is widely used by Japanese gastroenterologists to
treat fundal varices. This method uses a catheter through the
femoral vein, inferior vena cava, and left renal vein to occlude
feeding vessels of gastric varices; a large volume (40e50 mL)
of a sclerosant, ethanolamine, is injected shortly afterward.
BRTO is generally shown to be accompanied by satisfactory
outcomes and mild adverse effects. However, BRTO is per-
formed by radiologists and requires the presence of a gastro-
renal shunt. Therefore, BRTO has not been adopted by
gastroenterologists worldwide except for in Japan and Korea.
Two retrospective studies have compared TIPS and BRTO
in the treatment of gastric variceal hemorrhage. One study
from Korea included only 21 patients with active gastric var-
iceal bleeding and showed that BRTO could achieve hemo-
stasis and preventing rebleeding as effectively as TIPS.67 The
other study from Japan included 77 patients in the BRTO
group and 27 patients in the TIPS group.68 The cumulative
gastric variceal rebleeding rate at 1 year was 2% in the BRTO
group and 20% in the TIPS group. The survival rate was
Table 1
Complications of transjugular intrahepatic portosystemic stent shunt.
Types Complications Incidence (%)
Technical complications
Transcapsular puncture 33
Biliary fistula, hemobilia <5
Hemoperitoneum 1e2
Cardiac arrhythmias <1
Complete heart block <1
Fistula Rare
Nontarget organ
(gallbladder, colon, kidney)
rupture
Rare
Thrombotic-embolic
complications
Shunt stenosis, occlusion 18e78
Extensive thrombosis 3e15
Pulmonary emboli Rare
Disseminated intravascular
coagulation
Rare
Direct shunting-induced
complications
Heart failure Rare
Acute pulmonary edema Rare
Hepatic encephalopathy 20e40
Hepatic failure 5
Severe hyperbilirubinemia 5
Systemic complications
Bacteremia, sepsis 2e10
Fever not related to infection 1e5
Hemolytic anemia 10e15
Contrast-induced transient
kidney failure
Rare
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receiving BRTO than in those receiving TIPS. The survival
rate among Child-Pugh Class B and C was similar between
both therapies.
12. Use of TIPS in Taiwan and Asia
Though TIPS is well accepted in Western countries as a
treatment for portal hypertension, very few doctors in Taiwan
are willing to use it to handle variceal hemorrhage. The
handicap may be related to technique difficulty, fear of com-
plications such as hepatic encephalopathy or restenosis, or
possibly easier and successful control of variceal hemorrhage
by current endoscopic therapies. The most important factor
affecting the use of stents may be the lack of reimbursement
by the National Health Insurance Administration of Taiwan.
The first report regarding use of TIPS to address variceal
bleeding in Taiwan showed that 15 of 16 TIPS were techni-
cally successful.69 Unfortunately, two patients died from
hypovolemic shock and acute respiratory distress, respectively.
Among the six patients with active variceal bleeding, five
(83%) achieved hemostasis. Recurrent variceal bleeding
occurred in four patients (33%). Hepatic encephalopathy was
encountered in three patients (25%). However, Tzeng et al70
reviewed data from 107 patients receiving emergency TIPS
treatment for refractory variceal bleeding. Control of bleeding
was achieved in 61 of 73 patients (83%). However, rebleeding
developed in 50% of these patients by the 12th month of
follow-up and 23 patients (31%) died within 30 days of un-
dergoing the TIPS procedure. The poor outcome related to
these TIPS results may be because of application of TIPS as a
rescue therapy as well as inexperience with the technique.
Subsequently, with the improvement of technique, the use of
TIPS to prevent gastric variceal rebleeding showed a favorable
outcome.65 Based on published studies, it appears that TIPS is
also not popular in other Asian countries. In fact, BRTO is
more popular than TIPS in Japan and Korea.67,68 This may
explain why TIPS is rarely used in these countries for the
management of variceal hemorrhage. In China, a retrospective
analysis showed that early TIPS is more effective than endo-
scopic treatment in preventing variceal rebleeding and
improving survival, without increase the occurrence of hepatic
encephalopathy. In the other prospective study,71 TIPS com-
bined with coronary vein embolization was shown to increase
shunt patency and decrease rebleeding to 5.7%, compared with
20% in patients receiving TIPS alone.72
13. Discussion
The widespread use of TIPS in the treatment of portal
hypertension has been ongoing for more than 2 decades. The
TIPS device was created to substitute for the existing shunt
operation. The use of TIPS is advantageous because it obviates
the risk of mortality associated with surgical intervention.
Moreover, the use of TIPS instead of a surgical shunt could
theoretically decrease the disadvantages inherent in the
process of liver transplantation. However, a variety ofcomplications may be encountered.22,23 These complications
may be classified as technical, shunting-induced, and systemic
(Table 1). The occurrence of technical complications is pri-
marily related to operator technique. Variations in patients'
anatomy can be important factors leading to dismal outcomes.
Complications such as cardiac arrhythmia and hemoper-
itoneum may increase mortality rates, but can be reduced
through practice of the technique. Regional complications
such as shunt stenosis and occlusion are related to pseu-
dointimal hypertrophy.18 However, covered stents have been
documented to reduce the frequency of such complications.
Furthermore, postprocedure monitoring with Doppler ultra-
sound every 6 months is advisable.73 The flow velocity in the
stent is expected to be between 80 cm/second and 160 cm/
second shortly after TIPS.74 In case of shunt dysfunction, the
necessity of revision should be based on the clinical situation
at hand. The use of low-molecular-weight heparin in the im-
mediate postprocedure environment is believed to reduce the
risk of acute pulmonary embolism and the likelihood of
thrombosis.19 Recurrence of variceal bleeding episodes are
usually attributed to stenosis of the stents, and TIPS angiog-
raphy and pressure measurement are often required.66 TIPS
may be regarded as a side-to-side shunt and thus the devel-
opment of hepatic encephalopathy and hepatic failure after
placement of a stent may be unavoidable. In our own experi-
ence, prophylactic use of lactulose 20e30 mL per day could
prevent the occurrence of hepatic encephalopathy. On very
Table 3
Indications for TIPS for portal hypertensive bleeding.
Early TIPS for Child-Pugh Class B patients with active esophageal variceal
bleeding at endoscopy or Child-Pugh Class C
Refractory acute esophageal variceal bleeding by combination with
endoscopic and pharmacologic therapy
Recurrent esophageal variceal bleeding despite combination therapy with
banding ligation and beta-blockers
Esophageal varices bleeding with concomitant gastric varices
Gastric variceal bleeding, esophageal and fundal varices (GOV2)
Recurrent gastric variceal bleeding despite endoscopic therapy
Portal hypertensive gastropathy bleeding
Ectopic variceal bleeding
Prophylaxis of first variceal bleeding in patients with refractory ascites
TIPS ¼ transjugular intrahepatic portosystemic stent shunt.
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dice or hepatic encephalopathy may require occlusion of TIPS
to prevent hepatic failure or control encephalopathy. Smaller
diameter stents such as those less than 10 mm may elicit a
lower risk of hepatic encephalopathy and hepatic failure.
However, the effect of portal pressure decompression to less
than 12 mmHg may be reduced with a small-diameter stent.
The use of prophylactic antibiotics has not been shown to
reduce the incidence of infection rates.69 Some scholars still
advocate the use of prophylactic antibiotics to decrease bac-
terial infections. A detailed discussion of TIPS complications
and its management is presented in the study by Gaba et al.75
Though many complications have been associated with the use
of TIPS, most of these adverse events can be managed or
lessened by supportive therapies. The TIPS procedure is esti-
mated to be associated with a mortality of 1e2%. The use of a
covered stent is documented to be able to reduce TIPS
dysfunction and the incidence of hepatic encephalopathy.20
The contraindications are shown in Table 2. Older age, pre-
TIPS encephalopathy, Model for End-Stage Liver Disease
(MELD) score higher than 18 and serum bilirubin greater than
3 mg/dL are the most significant predictors of outcome and
may be regarded as relative contraindications.74,76 The in-
dications of TIPS are summarized in Table 3. Currently,
esophageal variceal bleeding can usually be managed with a
combination of pharmacologic therapy, EVL, and control of
gastric variceal bleeding by glue injection. Because of the
associated potential complications, however, TIPS has been
recommended as a rescue tool for treatment failure in acute
variceal bleeding or failure in prevention of variceal rebleed-
ing by a combination of pharmacologic and endoscopic ther-
apy. Early TIPS may be required for patients with a high risk
of treatment failure (i.e., Child-Pugh Class B with active
bleeding upon endoscopy or Child-Pugh Class C). TIPS may
also be advised for patients with concomitant prominent
esophageal and gastric varices, because many endoscopic
sessions may be required for these patients to achieve variceal
obliteration. For patients with prominent gastroesophageal
varices, with or without a history of bleeding, and the presence
of massive ascites, TIPS may also be a good option to “treat
two complications by one method”. TIPS has also been shown
to be effective for patients with ectopic variceal bleeding or
portal hypertensive gastropathy bleeding, but not in gastric
antral vascular ectasia.77e79 However, patients with contrain-
dications (Table 2) should not be considered for TIPS. PatientsTable 2
Contraindications to transjugular intrahepatic portosystemic stent shunt.
Right heart failure
Pulmonary hypertension
Severe encephalopathy
Polycystic liver disease
Hepatocellular carcinoma or cholangiocarcinoma
Portal vein thrombosis
Hepatic veins obstruction
Severe renal dysfunction
Systemic infectionpresenting with acute variceal bleeding associated with he-
patocellular carcinoma generally have a dismal prognosis.8 We
have encountered one case of advanced hepatocellular carci-
noma with intractable variceal bleeding by EVL and balloon
tamponade that was finally rescued by TIPS; the patient sur-
vived for more than 2 years. In addition, it has been demon-
strated that TIPS may influence first-line treatment of
hepatocellular carcinoma, resulting in impaired overall sur-
vival.80 Patients with acute variceal bleeding and poor liver
reserve as shown by Child-Pugh score greater than 12, Acute
Physiology and Chronic Health Evaluation II score greater
than 18 points, and serum bilirubin greater than 6 mg/dL have
a dismal outcome after TIPS.81 Thereafter, liver trans-
plantation should be considered if possible.
In conclusion, TIPS has been widely used in the treatment
of acute variceal bleeding and prevention of variceal
rebleeding. The use of TIPS is beneficial for troublesome
cases with variceal bleeding, but should be based on the
procedural expertise that exists at each hospital.
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